Targeted Screening for Alzheimer's Disease Clinical Trials Using Data-Driven Disease Progression Models

Heterogeneity in Alzheimer's disease progression contributes to the ongoing failure to demonstrate efficacy of putative disease-modifying therapeutics that have been trialed over the past two decades. Any treatment effect present in a subgroup of trial participants (responders) can be diluted b...

Descripción completa

Detalles Bibliográficos
Autores principales: Oxtoby, Neil P., Shand, Cameron, Cash, David M., Alexander, Daniel C., Barkhof, Frederik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Artificial Intelligence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204250/
https://www.ncbi.nlm.nih.gov/pubmed/35719690
http://dx.doi.org/10.3389/frai.2022.660581

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204250/
https://www.ncbi.nlm.nih.gov/pubmed/35719690
http://dx.doi.org/10.3389/frai.2022.660581

Ejemplares similares